In this episode, Kelvin Stott talks about why might be pharma's business model broken and how can it be fixed, the declining ROI on drug R&D, better R&D portfolio decision making, raising the bar in pharma/biotech innovation and more. 

Kelvin Stott has over 20 years of diverse leadership experience in pharma R&D strategy and operations, drug discovery and development, portfolio management, strategy consulting, biotech start-ups and venture capital. Currently, he is the Founder and CEO of Amporin Pharmaceuticals.

If you want to connect with us:
Linkedin: https://www.linkedin.com/company/cures-capital-podcast

YouTube - watch the interview:
https://www.youtube.com/@CuresCapital

If you want to connect with Kelvin or follow up on some of his work:
Linkedin: https://www.linkedin.com/in/kelvinstott/
Amporin Pharmaceuticals: https://www.linkedin.com/company/amporin/

Article: Pharma's broken business model - Part 1: An industry on the brink of terminal decline
Link: https://www.linkedin.com/pulse/pharmas-broken-business-model-industry-brink-terminal-kelvin-stott/

Article: Pharma's broken business model - Part 2: Scraping the barrel in drug discovery
Link: https://www.linkedin.com/pulse/pharmas-broken-business-model-part-2-scraping-barrel-kelvin-stott/

Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.